Natera on Tuesday announced the publication of a clinical experience study in Prenatal Diagnosis involving twin pregnancies and its Panorama noninvasive prenatal test (NIPT).
Panorama, conducted in the firm's CLIA-certified, CAP-accredited laboratory, assesses zygosity in twin pregnancies and reports individual fetal fractions in dizygotic (DZ) twins as early as nine weeks’ gestation, Natera said, adding that the test can also differentiate between maternal and fetal DNA to assess the risk of aneuploidies.
Using single-nucleotide polymorphism (SNP) technology, the test analyzes fetal DNA obtained through a blood draw from the mother.
The study’s investigators evaluated clinical outcomes from all cases at high risk in a pool of 18,984 twin pregnancy results gathered over 27 months.
Clinical outcomes were obtained from 105 high-risk cases, representing 51.2% of the reported high-risk results, Natera said.
“The results support the use of SNP-based NIPT as a first-line screening test for aneuploidy in twins with the added benefit of determining zygosity, which can assist with the early detection of complications of monochorionic twin gestations, such as twin-to-twin transfusion syndrome,” Dr. Herman Hedriana, senior author of the study, said in a statement.
Separately, Natera said it plans to present new clinical data this week on its tumor-informed molecular residual disease test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS).
